Beranda › Adenokarsinoma Esofagus › South Carolina
Uji klinis Adenokarsinoma Esofagus di South Carolina
6 studi untuk Adenokarsinoma Esofagus mencari peserta di lokasi di South Carolina.
Kota di South Carolina
Teks studi resmi (Bahasa Inggris)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Ralph H Johnson VA Medical Center, Charleston
- Medical University of South Carolina, Charleston
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Medical University of South Carolina, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05677490Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Medical University of South Carolina, Charleston
Menerima peserta
Usia 18 hingga 89 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Charleston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Prisma Health Cancer Institute, Greenville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06657144Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.